EU Approves GlaxoSmithKline JV's Juluca HIV Treatment
21 Mayo 2018 - 05:49AM
Noticias Dow Jones
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) said that its majority-owned joint
venture ViiV Healthcare has been granted marketing authorization by
the European Commission for its HIV treatment Juluca.
Juluca has been approved for HIV-1 in adults who are
virologically suppressed and who have been on an antiretroviral
treatment regimen for at least six months, the GlaxoSmithKline
said.
The treatment consists of two drugs in a single pill.
ViiV Healthcare Chief Executive Deborah Waterhouse said the
decision will allow patients to access a complete treatment program
that maintains low levels of the autoimmune virus with a single
pill.
Pfizer Inc. (PFE) and Shionogi Limited are minority shareholders
in ViiV Healthcare.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
May 21, 2018 06:34 ET (10:34 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024